Paperonium

← Back to the plain-language case

Reported overall 90-day mortality of 63.7% conflicts with the paper's own counts of 408 deaths

Lancet Reg Health Eur (2025) · doi:10.1016/j.lanepe.2025.101317 · PMC12266187

Summary

The abstract and the Results give the overall 90-day mortality of the 1109 included patients as "63.7% (n = 707)". Every breakdown of those same 1109 patients in the paper adds up to 408 deaths (36.8%) and 701 survivors (63.2%). The breakdowns are the three PROMISE risk groups, the two GRIm risk groups, and the PROMISE and GRIm death counts in the four cancer-type subgroups. The reported median overall survival of 4.78 months is longer than 90 days, which on its own requires 90-day mortality below 50%. The printed figure therefore overstates the cohort's primary-outcome event rate by 299 deaths, about 27 percentage points. It is also used in the Discussion to argue that mortality was higher than in the cohort in which PROMISE was developed.

What the paper reports

The headline figure, in the abstract:

PROMISE and GRIm scores were calculated for all 1109 patients, while CTI score was assessed in 333 patients with complete laboratory data. The 90-day mortality rate was 63.7% (n = 707).

— Abstract, Findings

The same figure opens the outcome paragraph of the Results, followed directly by the stratified counts:

The overall 90-day mortality rate was 63.7% (n = 707). For the PROMISE score, 271 patients (97.5%) in the low-risk group survived, with a 90-day mortality rate of 2.5% (n = 7). In the intermediate-risk group, 176 patients (81.9%) survived, and the 90-day mortality rate was 18.1% (n = 39). In the high-risk group, 254 patients (41.2%) survived, with a 90-day mortality rate of 58.8% (n = 362) (p < 0.0001). According to the PROMISE score, the median overall survival (OS) for the entire cohort was 4.78 months (95% CI: 4.29–5.28). For the GRIm score, the 90-day survival rate was 87.8% (n = 449) for low-risk patients and 42.2% (n = 252) for high-risk patients (p < 0.0001). The estimated median OS for the entire cohort was 4.63 months (95% CI: 4.14–5.12).

— Results, overall outcome paragraph

The risk-group sizes:

According to the PROMISE score, 278 patients (25.1%) were categorized as low risk, 215 patients (19.4%) as intermediate risk, and 616 patients (55.5%) as high risk. The GRIm score classified 511 patients (46.0%) as low risk and 598 patients (54.0%) as high risk.

— Results, patient characteristics paragraph (Table 1 column headers give the GRIm groups as "Low risk, n = 510 (46.0%) | High risk, n = 599 (54.0%)")

The cancer-type subgroups (PROMISE and GRIm sentences only; the CTI sentences refer to the 333-patient subset):

For lung cancer patients (n = 283), mortality rates based on the PROMISE score were 2.4% (n = 1) in the low-risk group, 3.6% (n = 2) in the intermediate-risk group, and 51.9% (n = 96) in the high-risk group (p < 0.0001). [...] The GRIm score showed a 7.9% (n = 9) mortality rate in the low-risk group and 53.3% (n = 90) in the high-risk group (p < 0.0001).

For gastrointestinal cancer patients (n = 350), the PROMISE score demonstrated mortality rates of 6.0% (n = 5) in the low-risk group, 23.7% (n = 18) in the intermediate-risk group, and 63.2% (n = 120) in the high-risk group (p < 0.0001). [...] The GRIm scores indicated a 13.6% (n = 20) mortality rate in the low-risk group compared to 60.6% (n = 123) in the high-risk group (p < 0.0001).

For breast cancer patients (n = 92), the PROMISE score revealed 90-day mortality rates of 2.8% (n = 1) in the low-risk group, 21.4% (n = 3) in the intermediate-risk group, and 59.5% (n = 25) in the high-risk group (p < 0.0001). [...] The GRIm score demonstrated mortality rates of 6.8% (n = 3) in the low-risk group compared to 54.2% (n = 26) in the high-risk group (p < 0.0001).

For patients with other cancers (n = 384), PROMISE score analysis showed no 90-day mortality in the low-risk group (n = 0), a mortality rate of 23.2% (n = 16) in the intermediate-risk group, and 60.8% (n = 121) in the high-risk group (p < 0.0001). [...] The GRIm scores revealed a 14.6% (n = 30) mortality rate in the low-risk group and 59.8% (n = 107) in the high-risk group (p < 0.0001).

— Results, section "Subgroup analysis by cancer type" ([...] marks omitted median-OS sentences)

The separately reported subset of 333 patients with a CTI score:

In this study, the 90-day mortality rate among 333 patients assessed using the CTI score was 35.1% (n = 117).

— Results, CTI subset paragraph

The Discussion:

According to the results of our study, the 90-day mortality rate was higher compared to the study by Mirallas et al., in which the PROMISE score was developed.

In the study by Mirallas et al., survival rates for low, intermediate, and high-risk groups were reported as 83.6%, 68.0%, and 33.4%, respectively.

— Discussion

Each quotation was checked against the article as archived in PubMed Central (src/show.py PMC12266187). Each one occurs exactly once (passages joined by [...] were checked sentence by sentence), and recompute.py.txt reruns that check.

What the paper's own numbers show

Method. The paper states that PROMISE and GRIm were calculated for all 1109 patients, and the PROMISE group sizes (278 + 215 + 616) and the cancer-type subgroup sizes (283 + 350 + 92 + 384) each sum to 1109. Each of these breakdowns is therefore exhaustive, and summing its death counts gives the cohort's total number of 90-day deaths. For PROMISE the paper gives deaths and survivors per group. For GRIm it gives survivors per group, so deaths are group size minus survivors, using either the text's or Table 1's group sizes. For the cancer types it gives deaths per risk group under each score. As an independent check, the Kaplan–Meier median OS is compared with the 90-day time point. The 333-patient CTI subset is recomputed the same way. No number was estimated; every input is a count or percentage printed in the text or Table 1. recompute.py.txt prints every value below and redraws both figures.

Quantity Location Reported Recomputed from the paper's own numbers
Overall 90-day mortality, 1109 patients Abstract, Findings; Results, outcome paragraph 63.7% (n = 707) 408 deaths, 36.8% (every row below). Arithmetic check: 707/1109 = 63.75%
PROMISE deaths, low + intermediate + high Results, outcome paragraph 7, 39, 362 (2.5%, 18.1%, 58.8% of 278, 215, 616) 7 + 39 + 362 = 408. Group percentages reproduce exactly
PROMISE survivors Results, outcome paragraph 271, 176, 254 271 + 176 + 254 = 701; 408 + 701 = 1109
GRIm deaths (group size − survivors) Results, outcome paragraph; Table 1 survivors 449 (87.8%), 252 (42.2%); n 510/599 (Table 1) or 511/598 (text) (510 − 449) + (599 − 252) = 61 + 347 = 408; with text n, 62 + 346 = 408. Survivors 449 + 252 = 701
Deaths by cancer type, PROMISE Results, "Subgroup analysis by cancer type" lung 1+2+96, GI 5+18+120, breast 1+3+25, other 0+16+121 99 + 143 + 29 + 137 = 408 (n = 1109)
Deaths by cancer type, GRIm Results, "Subgroup analysis by cancer type" lung 9+90, GI 20+123, breast 3+26, other 30+107 99 + 143 + 29 + 137 = 408; per cancer type identical to PROMISE
Median OS vs 90-day mortality Results, outcome paragraph median OS 4.78 months ("According to the PROMISE score"); 4.63 months (stated after the GRIm results) Both exceed 90 days (2.96 months), so Kaplan–Meier survival at 90 days is above 50% and 90-day mortality is below 50%. 707 deaths within 90 days would force Kaplan–Meier mortality at 90 days to at least 63.8% and the median below 90 days
CTI subset, 333 patients Results, CTI subset paragraph 35.1% (n = 117) 117/333 = 35.1%. Also (166 − 147) + (167 − 69) = 117; PROMISE within subset 3 + 12 + 102 = 117; Combined score 0 + 1 + 116 = 117; CTI by cancer type 21 + 40 + 20 + 36 = 117. Consistent
Gap between stated and recomputed — 707 (63.7%) 707 − 408 = 299 deaths; 63.75 − 36.79 = 27.0 percentage points

Four exhaustive breakdowns, drawn from two scores and two different groupings of the same patients, agree on 408 deaths. They also agree on 701 survivors where survivors are given. The subset of 333 patients, reported the same way, is fully consistent, so the reporting of the stratified counts can be reproduced throughout. Only the single overall figure departs from them. Its percentage, 63.7%, is close to the share who survived (701/1109 = 63.2%), not the share who died.

Figure

Death counts: stated 707 versus 408 from each of the paper's four exhaustive breakdowns

Figure 1. Number of the 1109 included patients who died within 90 days. The orange bar is the overall figure printed in the abstract and Results (707, "63.7%"). Each blue bar sums the death counts the paper itself reports for one exhaustive breakdown of the same 1109 patients: the three PROMISE risk groups, the two GRIm risk groups (group size from Table 1 minus reported survivors), and the PROMISE and GRIm deaths in the four cancer-type subgroups. Segments are drawn in the order the formula on each row lists them; unlabeled thin segments are 7, 39 and 29. The dashed line marks the cohort size. All four breakdowns give 408 deaths (36.8%). Values come from the article text and Table 1 and are recomputed by recompute.py.txt.

Percentages: printed mortality, recomputed mortality and survival, CTI subset, and the 50% bound implied by median OS

Figure 2. The same comparison as percentages on one 0–100% axis. The printed overall mortality (orange, 63.7%) lies in the shaded region that the paper's own median OS of 4.78 months rules out. A Kaplan–Meier median longer than 90 days means fewer than half the patients had died by day 90. The mortality recomputed from the strata (36.8%) lies outside it. The printed value sits next to the recomputed survival share (blue diamond, 63.2%). The bottom row shows the separately reported CTI subset, where the reported value (orange ring) and the recomputed value (blue dot) coincide at 35.1%.

Why it matters

Explanations considered

Status

Suggested correction

In the abstract (Findings) and in the first sentence of the Results outcome paragraph, replace "63.7% (n = 707)" with the figure supported by the stratified data, which on the paper's counts is 36.8% (n = 408), after confirming it against the source dataset. In the Discussion, revisit the statement that 90-day mortality was higher than in the PROMISE development study, and the explanation offered for it, in light of the corrected rate. Two further points could be checked at the same time. One is the GRIm group sizes (511/598 in the text vs 510/599 in Table 1). The other is the predictive values in Table 2, which do not correspond to the 35.1% event rate of the 333-patient subset; giving the underlying 2×2 counts would let readers verify them.